U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N3S
Molecular Weight 209.311
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALIPEXOLE

SMILES

NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DHSSDEDRBUKTQY-UHFFFAOYSA-N
InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)

HIDE SMILES / InChI

Molecular Formula C10H15N3S
Molecular Weight 209.311
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

Originator

Curator's Comment: # Boehringer Ingelheim Pharma KG

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.8 null [pKi]
7.0 null [pKi]
7.43 null [pKi]
7.09 null [pKi]
7.37 null [pKi]
6.48 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
2001 Apr 6
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
2001 May 1
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
2001 Oct
Alpha2-adrenoceptor ligands inhibit alpha1-adrenoceptor-mediated contraction of isolated rat arteries.
2002 Aug
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
2003 Apr
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
2003 Aug
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area.
2003 Aug 21
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.
2007
Pharmacological modulation of dopaminergic brain activity and its reflection in spectral frequencies of the rat electropharmacogram.
2008
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
2008 Mar
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
2008 Nov 19
Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
2009 Nov 5
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.
2010 May
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
2010 Oct
Patents

Patents

Sample Use Guides

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day
Route of Administration: Oral
In Vitro Use Guide
Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:37:10 GMT 2023
Edited
by admin
on Fri Dec 15 17:37:10 GMT 2023
Record UNII
7AM2J46Z1Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALIPEXOLE
INN   MI   WHO-DD  
INN  
Official Name English
6-ALLYL-2-AMINO-5,6,7,8-TETRAHYDRO-4H-THIAZOLO(4,5-D)AZEPINE
Systematic Name English
talipexole [INN]
Common Name English
Talipexole [WHO-DD]
Common Name English
TALIPEXOLE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
Code System Code Type Description
MERCK INDEX
m10441
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
TALIPEXOLE
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
SMS_ID
100000082998
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
EVMPD
SUB10805MIG
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
DRUG CENTRAL
2558
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
MESH
C024763
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
FDA UNII
7AM2J46Z1Y
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
PUBCHEM
5374
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
CAS
101626-70-4
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
NCI_THESAURUS
C152496
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID8046321
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL279085
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
INN
5973
Created by admin on Fri Dec 15 17:37:10 GMT 2023 , Edited by admin on Fri Dec 15 17:37:10 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY